CHEK2 and breast carcinoma: In fact, in a study of over 6000 CHEK2 carriers (excluding the CHEK2 I157T and S428F GPVs, which were analyzed separately), there were no differences in breast cancer risk between missense and truncating CHEK2 GPVs [3].